Quick answer
How was CJC-1295 developed? In 1982 two groups isolated growth-hormone-releasing factor from human pancreatic tumors; the first 29 residues kept full activity; in 1986 plasma dipeptidyl peptidase cleavage of the N-terminus was shown to inactivate it; stabilized analogs such as modified GRF(1-29) followed; and in 2005 ConjuChem scientists reported that attaching a maleimide group lets the analog bind albumin in vivo, naming it CJC-1295. The no-DAC product is the modified fragment without that group. Sold by V8 for laboratory research use only.
Compounds sold today are the end of a forty-year chain of papers. Reading that chain explains why the molecule has the sequence it does, why “DAC” and “no DAC” exist as terms, and why the literature’s duration claims belong to one form or the other. This is a timeline built from primary sources, with each step tied to its citation; it complements the shorter history section in the CJC-1295 No DAC research overview. For laboratory research use only; not for human consumption.
Timeline at a glance
| Year | Step | Source |
|---|---|---|
| 1982 | GH-releasing factor isolated from human pancreatic tumors that caused acromegaly | Guillemin and colleagues; Rivier and colleagues |
| 1985 | Pulsatile, not continuous, GRF(1-29)NH2 shown to drive growth in rats | Clark and Robinson |
| 1986 | Plasma dipeptidyl-aminopeptidase cleavage of GRH(1-44) to inactive GRH(3-44) described | Frohman and colleagues |
| 1992 | Pituitary GHRH receptor cloned | Mayo |
| 2004 | GHRH knockout mouse created as a model of isolated GH deficiency | Alba and Salvatori |
| 2005 | Albumin bioconjugates of hGRF(1-29) reported; CJC-1295 identified | Jetté and colleagues |
| 2006 | Once-daily CJC-1295 in GHRH knockout mice | Alba and colleagues |
1982: GHRH from pancreatic tumors
The stimulatory hypothalamic factor for GH proved hard to find, and it surfaced in an unexpected place: in 1982 the groups of Guillemin and of Rivier, Vale and colleagues purified GH-releasing factors from pancreatic tumors removed from people with acromegaly, where ectopic production explained the excess GH (Guillemin and colleagues, 1982; Rivier and colleagues, 1982). Tumor tissue gave enough material to sequence the factor. The hypothalamic 44-residue peptide, GHRH(1-44), was then characterized, and short fragments were tested for activity. Work with the N-terminal fragment GHRF(1-29)-amide showed that it is active in vivo (Clark and Robinson, 1985), and every later analog rests on that fragment. The shortest active fragment, GHRH(1-29)-amide, is the compound known as sermorelin, covered in the sermorelin overview.
1985–1992: pattern matters, and plasma destroys the peptide
By the mid-1980s two practical facts about GRF(1-29) were known. First, its biology depends on the pattern of exposure: in rats, pulsatile intravenous infusion promoted growth and pituitary GH content, whereas continuous infusion at the same daily amount did not (Clark and Robinson, 1985). Second, it is short-lived. Frohman and colleagues (1986) showed that in human plasma a dipeptidyl-aminopeptidase removes the first two residues of GRH(1-44), leaving a GRH(3-44) product with less than one-thousandth of the activity; the half-life of the intact 44-mer by HPLC was 17 minutes in plasma in vitro.
The receptor was cloned in 1992, showing a pituitary-specific class B receptor (Mayo, 1992). From then on a ligand could be studied against a defined molecular target, not only through hormone release.
The modification logic: protect the weak points
The analogs that followed answered two weaknesses of the native fragment, the N-terminal cleavage site and oxidation-prone residues. Replacing alanine at position 2 with its D-isomer blocks the peptidase; further substitutions at other positions reduce additional liabilities. The result is the modified GRF(1-29) in the CJC-1295 (No DAC) listing, whose sequence begins Tyr-D-Ala-Asp-Ala-Ile-Phe. It has a longer working life than the unmodified fragment in assay media but remains a short-acting analog, which suits pulse-type designs (see tesamorelin versus CJC-1295 for another stabilization strategy).
2005: adding an albumin anchor
A different route to longevity was to extend circulating half-life by attaching the peptide to albumin. Jetté and colleagues (2005), working at ConjuChem, made three maleimido derivatives of hGRF(1-29), conjugated them to human serum albumin ex vivo and showed greater stability against dipeptidyl peptidase IV and bioactivity in cultured rat pituitary cells. In rats, the best compound gave a four-fold increase in GH area under the curve over two hours relative to hGRF(1-29) and remained in plasma beyond 72 hours. It was named CJC-1295. The initials trace to the company; the “DAC” in later usage refers to the drug affinity complex, the reactive maleimide-linked lysine. The version without it became known as “no DAC” to avoid confusion.
A year later, once-daily CJC-1295 in GHRH knockout mice, a model created in 2004, maintained normal body weight and length over five weeks, while less frequent schedules were less effective (Alba and colleagues, 2006; Alba and Salvatori, 2004). The DAC compound is described in the DAC research overview, and the differences are tabulated in DAC versus no DAC.
Why history matters to a bench scientist
| Name in the literature | What it denotes |
|---|---|
| GHRH(1-44), GRH, GRF | The full native releasing hormone |
| GHRH(1-29)-NH2, hGRF(1-29), sermorelin | The shortest fully active native fragment |
| Modified GRF(1-29), mod-GRF, CJC-1295 without DAC | Stabilized fragment without an albumin anchor |
| CJC-1295, CJC-1295 with DAC | Stabilized fragment with maleimide-lysine for albumin binding |
- Naming. “CJC-1295” in 2005 meant the albumin-binding compound. Later vendors and authors use it loosely, so read the sequence and form.
- Duration claims. Multi-day plasma presence belongs to the conjugated molecule; the unconjugated analog acts over a much shorter window.
- Models. The knockout mouse and the pulsatile-infusion rat are the reference preclinical designs; an experiment that departs from them has no direct precedent.
- Manufacture. Short modified sequences became routine because solid-phase synthesis, is reproducible and scalable.
Analytical consequences are covered in understanding HPLC purity and understanding amino acid sequences. For the sibling analog with a different design, see the tesamorelin overview.
What the record does not show
The primary papers establish chemistry and animal pharmacology. They do not establish equivalence between the DAC and no-DAC molecules, and the no-DAC compound has fewer dedicated primary studies than the DAC compound. Statements about it generally rest on the behavior of related stabilized GHRH analogs, which should be flagged as inference when cited. Product details (purity ≥98% by HPLC, 5 mg and 10 mg lyophilized vials, storage 2–8 °C with −20 °C long term) are on the product page, with certificates in the COA library where published. Concentration arithmetic for a dissolved vial is mass ÷ volume; see the calculator.
Frequently asked questions
Who discovered growth-hormone-releasing hormone?
In 1982, groups led by Guillemin and by Rivier, Vale and colleagues isolated and characterized GH-releasing factors from human pancreatic tumors associated with acromegaly.
Why is the GHRH fragment 29 residues long?
Early work found that the first 29 residues of the 44-residue hormone kept full activity, so GHRH(1-29)-amide became the standard minimal active fragment.
Why was native GHRH unsuitable as a reagent?
In plasma a dipeptidyl-aminopeptidase removes the first two residues, producing a product with under one-thousandth of the activity (Frohman and colleagues, 1986).
What does CJC stand for?
The prefix comes from ConjuChem, the company whose scientists reported the albumin-binding analog in 2005.
What does DAC stand for?
Drug affinity complex: the reactive maleimide-linked lysine that bonds the peptide to albumin in vivo.
What is CJC-1295 without DAC?
A modified GRF(1-29) analog with protective substitutions but no albumin-binding group, behaving as a short-acting GHRH analog.
When was the GHRH receptor cloned?
1992, as a pituitary-specific receptor (Mayo, 1992).
What animal models define the field?
The pulsatile-infusion rat (Clark and Robinson, 1985) and the GHRH knockout mouse (Alba and Salvatori, 2004; Alba and colleagues, 2006).
Does the history prove anything about the no-DAC product?
It explains its design. Primary evidence for the no-DAC compound specifically is thinner than for the DAC compound, and related-analog inference should be marked as such.
Is this a usage guide?
No. It is a literature history. V8 supplies the peptide for laboratory research use only.
Related reading: CJC-1295 and IGF-1: What Animal Studies Measured, CJC-1295 Mechanism of Action: GHRH Receptor Signaling, CJC-1295 in Metabolic and Endocrine Research Models.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
- Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0
- Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the N terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
- Alba M, Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated GH deficiency. Endocrinology. 2004;145(9):4134-4143. doi:10.1210/en.2004-0119
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
